1739s4121
NM_001098424.1 NM_001204386.1 NM_001204387.1 NM_001204388.1 NM_001290983.1 NM_004087.2 XM_005269289.3 XM_011512502.2 XM_011512503.1 XM_011512505.1 XM_011512506.1 XM_011512509.1 XM_017005800.1 XM_017005801.1 XM_017005802.1 XM_017005803.1 XM_017005804.1 XM_017005805.1 XM_017005806.1 XM_017005807.1 XM_017005808.1 XM_017005809.1 XM_017005810.1 XM_017005811.1 XM_017005812.1 XM_017005813.1 XM_017005814.1 XM_017005815.1 XM_017005816.1 XM_017005817.1 XM_017005818.1 XM_017005819.1 XM_017005820.1 XM_017005821.1 XM_017005822.1 XM_017005823.1 XM_017005824.1
14%(+/-3% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00177739_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.